By Chris Wack
Enochian BioSciences Inc. Monday said it completed an investigator pre-investigational new drug process following receipt of written comments from the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research Office of Tissues and Advanced Therapies.
The company said the request was based on the results of a 54-year old man living with HIV who had failed to suppress the virus with antiviral therapy. The patient subsequently stopped taking ART and received an innovative treatment developed by SRI.
Enochian BioSciences holds the exclusive license for the product.
The company said the patient's HIV infection blood levels were controlled more effectively for 365 consecutive days off ART using the SRI treatment compared to what had previously been achieved with ART.
Enochian shares rose 3% to $8.90 in premarket trading.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires